Truist analyst Richard Newitter raised the firm’s price target on Medtronic (MDT) to $110 from $103 and keeps a Hold rating on the shares. The company’s PFA, or pulsed field ablation, driven revenue beat was accompanied an acceleration outlook for the CAS, Cardiac Ablation Solutions, segment, supporting a solid new product narrative heading into 2026, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT: